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ABSTRACT
Objective The aim of this paper is to describe the 
stages undertaken to generate the items and conceptual 
framework of a new electronic personal assessment 
questionnaire for vascular conditions.
Design A mixed methods study: First a survey of 
vascular clinicians was completed to identify the most 
common conditions treated in vascular clinics and wards. 
Quantitative systematic reviews were done to identify 
validated patient- reported outcome measures (PROMs) 
for direct inclsuion in the new instrument. However, due 
to scarcity of validated PROMs, the items of the new 
instrument were mainly based on a large qualitative study 
of patients and systematic reviews of the qualitative 
evidence . This was followed by a quantitative clinicians’ 
consensus study and, inally, a qualitative face validity 
study with patients.
Participants Vascular patients participated in the 
primary qualitative study and the face validity study. In the 
qualitative study, 55 patients were interviewed, and for the 
face validity, 19 patients gave feedback. Twelve clinicians 
completed the survey and 13 completed two cycles of the 
clinicians’ consensus study.
Results The items and scales in the electronic personal 
assessment questionnaire for vascular conditions 
(ePAQ- VAS) were generated based on the results of 
ive systematic reviews evaluating existing PROMs for 
possible inclusion in ePAQ- VAS, ive systematic reviews 
of qualitative evidence, a primary qualitative study 
involving 55 patients and clinicians’ input. One hundred 
and sixty- eight items were initially generated, of which 
59 were eliminated by the expert panel due to repetition. 
The instrument was divided into one generic and three 
disease- speciic sections (abdominal aortic aneurysm, 
carotid artery disease and lower limb vascular conditions). 
In each section, items were grouped together into putative 
scales. Fifty- ive items were grouped across eight scales; 
the remaining items were kept as individual items, 
because of relevance to service users.
Conclusions This multidimensional electronic 
questionnaire covers the most common vascular 
conditions. This is particularly important for patients 
presenting with mixed symptoms or multiple conditions. 
This tool captures symptomatology, health related quality 
of life (HRQoL) and other clinically relevant data, such as 
experience with services and comorbidities.
INTRODUCTION
Vascular conditions can cause problems 
throughout the body; epidemiological studies 
suggest that both venous and arterial diseases 
are very common.1 2 It therefore makes sense 
to assess individuals with vascular disease 
holistically, investigating existing or poten-
tial manifestations of vascular disease and the 
impact of conditions on health- related quality 
of life. Patient- reported outcome measures 
(PROMs) are questionnaires or instruments, 
designed to elicit information directly from 
the patient and can be used as part of such 
an assessment.
Strengths and limitations of this study
 Ź This electronic patient assessment questionnaire for 
vascular conditions was developed with input from 
patients and clinicians.
 Ź The themes generated from previously published 
ive comprehensive qualitative reviews and a qual-
itative study of vascular patients were used to de-
velop the items.
 Ź Vascular clinicians were surveyed to ensure clinical-
ly relevant conditions and questions were included.
 Ź The burden of questionnaire is its main limitation; 
however, providing strict skipping rules, the patient 
were only be presented with the relevant sections 
and questions of the instrument.
 Ź The face validity study examined the clarity and rel-
evance of the items; however, the comprehensive-
ness of these PROMs was not assessed.
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Validity and reliability are integral to developing or 
selecting a PROMs. A key aspect of validity is content 
validity, and international guidelines including the US 
Food and Drug Administration (FDA) guidance stress the 
importance of this psychometric property.3
Many generic and condition specific PROMs have been 
adopted to examine impact of vascular conditions on 
patients and measure outcomes. This is despite a lack of 
evidence that they have been developed and evaluated 
in- line with accepted guidelines; in addition, these instru-
ments are rarely used or formally evaluated in routine 
patient assessment in day- to- day clinical practice. We 
conducted scoping searches and informal discussions 
with vascular clinicians to identify any existing PROMs; 
however, these preliminary stages in the research process 
suggested an absence of valid and reliable PROMs for use 
in vascular populations.
In this paper, we report the stages in developing an 
electronic personal assessment questionnaire for vascular 
patients (ePAQ- VAS). This includes:
1. Identifying the main vascular conditions to be includ-
ed in this electronic measure based on a survey of cli-
nicians treating vascular disease.
2. Developing a hypothesised framework for the sections 
for different disease categories based on the previous 
systematic reviews that identified PROMs used in pa-
tients with abdominal aortic aneurysm (AAA), carot-
id artery disease (CAD), peripheral arterial disease 
(PAD), venous leg ulcers (VLU) and varicose veins 
(VV).4–8
3. Developing the items within each section of ePAQ- VAS 
based on qualitative systematic reviews9–12 and a prima-
ry qualitative study.13
4. A consensus study with clinicians to rate the relevance 
of included items and to add items to ePAQ- VAS based 
on the opinion of vascular surgeons, radiologists and 
nurses.
5. A face validity study with vascular patients to examine 
the clarity and relevance of the items within ePAQ- VAS.
The aim of these steps was to develop a single electronic 
instrument covering most vascular conditions in line with 
international guidance.3 The conceptual framework and 
items were developed in a way to ensure this assessment 
tool can be used in patients with mixed symptoms and 
multiple vascular conditions. Every patient to receive a 
unique voucher code along with their clinic letters. The 
code can be used to access and complete ePAQ- VAS at 
home or in the outpatient clinic using computers or 
other electronic devices.
The server of ePAQ is hosted and integrated with 
National Health Service (NHS) N3- based informatics 
systems. Other ePAQ questionnaires such as ePAQ- 
Pelvic floor and ePAQ- preassessment are in clinical use 
in different NHS hospitals. ePAQ Ltd is an NHS spin- out 
technology company, and the patient data collected by 
the company can be linked to the unique NHS number 
of each patient, and although there is a lack of integrated 
Figure 1 Development of ePAQ- VAS conceptual framework. 
PROMs, patient- reported outcome measures; ePAQ- VAS, 
electronic personal assessment questionnaire for vascular 
patients.
Table 1 Results from the systematic reviews of psychometric evaluation of vascular PROMs
Condition
Number of 
citations
Number of 
included 
papers Results Conclusions
AAA 1232 3 4 validated PROMs identiied: 1 
generic, 1 vascular generic and 2 
condition speciic
This review has highlighted a gap in the 
evidence for validated PROMs in AAA. Due to 
a lack of rigorous psychometric testing.
CAD 1670 5 6 validated PROMs identiied:
4 generic and 2 condition speciic
There was a lack of validated PROMs to 
measure outcomes for CAD patients.
PAD 6981 14 13 validated PROMs identiied:
6 generic and 7 condition speciic
VascQol was the most psychometrically robust 
instrument.
VV 3879 7 3 validated PROMs identiied:
1 generic and 2 condition speciic
Aberdeen Varicose Vein Questionnaire is the 
most psychometrically robust disease- speciic 
PROMs for use with VV patients.
VLU 3879 7 validated PROMs identiied:
3 generic and 4 condition speciic
The most valid and reliable condition speciic 
PROMs was VLU-QOL.
AAA, abdominal aortic aneurysm; CAD, carotid artery disease; PAD, peripheral arterial disease; VLU, venous leg ulcer; VLU- QOL, venous leg 
ulcer quality of life; VV, varicose veins.
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digital infrastructure in the NHS, the technology is avail-
able for future use to link records collected by different 
NHS providers.
METHODS
Clinicians involved in the care of vascular patients were 
invited to identify the common vascular conditions 
treated by vascular surgeons and vascular specialists. They 
were asked to list the key issues, symptoms and the impact 
of these conditions on patients suffering with these 
diseases. Data from this round were used to inform quali-
tative evidence synthesis.
The conceptual framework of ePAQ- VAS was based on 
primary qualitative interviews with vascular patients, input 
from clinicians, systematic reviews examining the validity 
of existing PROMs and qualitative reviews of the impact 
of vascular diseases on quality of life. Figure 1 illustrates 
the process used to develop ePAQ- VAS in accordance to 
s guidelines.3
Systematic reviews to identify and appraise existing PROMs
Systematic searches were conducted of bibliographic 
databases including CINAHL via EBSCO, MEDLINE and 
MEDLINE in Process via Ovid, Embase via Ovid, PsycINFO 
via Ovid, Social Science Citation Index/Science Cita-
tion Index via Web of Science (Thomson Reuters) and 
Proquest dissertations and theses. PROMs were included 
where there was evidence that they had undergone some 
form of psychometric evaluation that would allow the 
validity, reliability and responsiveness of the PROMs to 
be assessed. Included PROMs were categorised per type 
(generic or condition specific) and the vascular popula-
tion(s) in which they had been validated. Quality assess-
ment3 14 was conducted to identify high- quality existing 
PROMs for possible direct inclusion in ePAQ- VAS or 
to be used as a basis to inform the qualitative evidence 
synthesis. For further information about the appraisal 
criteria to examine the robustness of the psychometric 
analysis and samples of search strategies, please see the 
online supplementary materials.
Table 2 Participant characteristics of the primary qualitative study
AAA CAD PAD VV VLU Total
Gender, n (%)
  Male 10 (77) 5 (56) 11 (79) 5 (50) 8 (80) 39 (70)
  Female 3 4 3 5 2 17
Age range (mean) 53–87
(72)
52–86
missing
47–82
(69)
35–77
(50)
47–84
(59)
35–87
missing
AAA, abdominal aortic aneurysm; CAD, carotid artery disease; PAD, peripheral arterial disease; VLU, venous leg ulcers; VV, varicose veins.
Table 3 Findings from the primary qualitative study with vascular patients
Condition Sample size Key indings
AAA 13 No physical symptoms, a small number of participants reported abdominal pain and pain in their 
legs. Uncertainty, anxiety and fear of rupture and death appeared to impact most greatly on 
people’s QoL.
CAD 9 This condition seemed to have had the least impact on physical and social function, although 
psychologically it created a sense of worry and anxiety for some participants. The main reported 
outcome was fear of having a major stroke.
PAD 14 Pain and mobility were the most commonly reported themes. The extent to which they impacted 
on QoL was associated with the severity, age expectations and social support. Fear of the 
symptoms worsening and amputation was evident.
VV 10 VV do not appear to have had a major impact on overall QoL for most the participants. Pain was 
the most common issue. The perceived unpleasant appearance of the VV seemed to have the 
greatest psychological impact. Many of the participants had had their VV for very long periods of 
time, often just ‘putting up with it’ for numerous years before seeking help.
VLU 10 The impact of VLU on QoL differed within the group. For some, there were no major issues, 
and having a VLU was accepted as part of their current life, with the hope that it would heal 
eventually. For others, there was a far more signiicant effect. Pain was quite severe for 
some participants leading to a signiicantly reduced QoL. VLU appeared to have a signiicant 
psychological impact causing a high degree of distress for some.
AAA, abdominal aortic aneurysm; CAD, carotid artery disease; PAD, peripheral arterial disease; QoL, quality of life; VLU, venous leg ulcer; VV, 
varicose veins.
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Primary qualitative study
Semistructured interviews were conducted with 55 
vascular patients from Sheffield Teaching Hospitals 
NHS Foundation Trust following purposeful sampling 
to ensure a range of participants of different age and 
gender, at different stages of treatment and covering 
the main five vascular conditions (AAA, PAD, CAD, VLU 
and VV). A consultant vascular surgeon or specialist 
nurse approached each patient either in clinic or over 
the telephone to explain about the project and ask if the 
patient would be interested in participating in the study. 
If the initial approach was by the clinician in clinic, the 
researcher would then speak to the patient and give 
further information about the project including a partic-
ipant information sheet (PIS) before taking contact 
details. For those patients who were first contacted over 
the phone, the clinician would then gain verbal consent 
to pass on their contact details to a researcher. Copies of 
the PIS were sent out through the mail to those who had 
not been initially approached in clinic. The researcher 
gave at least 24 hours for the patient to read through 
the PIS and consider the information before contacting 
each person by telephone to ask if they would be inter-
ested in participating in an interview. If they were inter-
ested in taking part, a date and time was agreed for a 
researcher to visit the participant at home to carry out 
an interview. Questions were asked about the signs, 
symptoms and impact of the condition on function and 
lifestyle. On the day of the interview, the trained quali-
tative researcher checked if the participant understood 
the PIS and took informed written consent. Field notes 
Table 4 Map of symptoms and quality of life concepts 
across ive conditions
PAD AAA CAD VV VLU
Symptoms
No symptoms × ×
Pain × × × × ×
Neck pain ×
Leg pain × × × × ×
Abdominal pain × ×
Arm pain ×
Cramp/aching × × × ×
Burning sensation ×
Pain severity × × × × ×
Pain on walking × × × ×
Pain at rest × ×
Pain when 
standing
× x
Mobility x x x x x
Distance x x x x
Speed x x
Stairs/slopes x x
Non- healing 
wounds
x x
Comorbidities x x x x
Progression of 
symptoms
x x x x
Sleep x x x x
Swelling x x
Loss of balance x
Confusion x
Impact on 
physical 
functioning
Hobbies x x x
Exercise x x x x
Daily activities x x
Social impact
Travel x x x
Social activities x x x x
Social support x x x
Psychological 
impact
Anxiety x x x x x
Depression x x x
Feelings of loss x x x
Health 
expectations
x x x x x
Unsightly 
appearance
x
Continued
PAD AAA CAD VV VLU
Feeling self- 
conscious
x x x
Fear of worsening 
symptoms
x x x x x
Fear of rupture 
death
x
Fear of 
amputation
x x
Fear of stroke ×
Financial impact
Income × × ×
Time off work × ×
Lifestyle
Smoking × × × × ×
Exercise × × × ×
Diet × × × ×
Weight × ×
AAA, abdominal aortic aneurysm; CAD, carotid artery disease; 
PAD, peripheral arterial disease; VLU, venous leg ulcer; VV, 
varicose veins.
Table 4 Continued
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were taken to aid interpretation of the interview data. 
Each interview was recorded and transcribed verbatim. 
Personal details were removed from the transcript to 
enhance participant anonymity. The interview tran-
scripts were typed and uploaded into NVIVO V.11 (QSR 
International, Warrington, UK) for management and 
analysis.
Systematic reviews of the qualitative evidence
Systematic searches of the following databases; CINAHL 
via EBSCO, MEDLINE and MEDLINE in Process via 
Ovid, Embase via Ovid, PsycINFO via Ovid, Social 
Science Citation Index/Science Citation Index via Web 
of Science (Thomson Reuters) and Proquest dissertations 
were conducted to identify existing qualitative research 
detailing vascular patients’ experience of living with AAA, 
PAD, CAD, VLU and VV. For further samples of search 
strategies, please see the online supplementary materials.
Analysis of the qualitative evidence
Qualitative data from the primary study and each of the 
systematic qualitative reviews were analysed separately. 
Framework analysis was used to analyse the interviews.15 
This analysis includes five stages:
 Ź The first stage involved familiarisation by reading of 
the transcripts and reading the primary data.
 Ź The second stage involved identification of a thematic 
framework; the thematic framework was based either 
on clinical opinion for areas with no valid PROMs, 
such as AAA and CAD, or a combination of clinical 
opinion and, when available, the scales of PROMs 
with good content validity.
 Ź In the third stage, the data were coded and indexed 
by applying the thematic framework to the whole 
data set until saturation was achieved. An second 
researcher checked all the themes that were identi-
fied, and differences in were discussed and adjusted 
involving a third senior author (GJ).
 Ź At the fourth stage, a framework matrix was created by 
arranging the data per the thematic references.
 Ź Finally, mapping and interpretation, including exam-
ining patterns within the data and associations with it.
Clinicians’ input and consensus exercise
Twenty- three clinicians involved in the care and manage-
ment of patients with vascular conditions were invited 
to a survey to list the most common vascular conditions 
managed by them and to list the key issues, symptoms and 
the impact of these diseases on patients. Data from this 
round were used to inform qualitative evidence synthesis.
Different group of clinicians involved in the care of 
vascular patients were invited to a consensus study to 
score the relevance of items (questions) in the provi-
sional version of ePAQ- VAS. In total, 30 clinicians 
including vascular surgeons, interventional radiologists, 
vascular nurses, physiotherapists and occupational ther-
apists were invited. Participants were asked to rate the 
appropriateness of each question on a 5- point Likert 
scale of ‘strongly disagree’ (=0) to ‘strongly agree’ (=4). 
This process was repeated, and members of the clinicians’ 
panel were presented with the aggregate findings of the 
previous round and again asked to score each question. 
This process aimed to examine the relevance of each item 
from the clinicians’ perspective and to identify any new 
items suggested by the clinicians.16
Developing scales and items
The ePAQ development team (AA, EL, PP, GJ and SR) 
employed an iterative process, incorporating evidence 
from the systematic reviews, qualitative study and the 
clinicians’ consensus study. In line with the FDA guid-
ance, 3 items (questions) were developed from the quali-
tative data using the following three steps: interpretation, 
translation and triangulation of themes.
Interpretation involved familiarisation with the language 
used in the primary data included in the synthesis. This 
enabled translation of descriptions of apparently diverse 
issues affecting vascular patients into a single set of 
harmonised themes. The resulting themes were used to 
develop the items for ePAQ- VAS. The items were grouped 
into sections, and each section further divided into scales 
consisting of a connected group of items. Triangulation 
was performed across evidence sources to ensure the 
items comprehensively covered all issues of importance 
to patients with AAA, PAD, CAD, VLU and VV.
Table 5 Results from qualitative reviews examining the impact of the major vascular conditions on quality of life
Condition
Numbers of 
citations
Number of 
included 
studies Key themes
AAA 315 3 Anxiety and lack of physical symptoms.
CAD 964 3 Symptoms, psychological and social impact, risk and service experience.
PAD 973 9 Pain, compromised physical function and impact on social life.
VV 1804 3 Adaptation – coping strategies employed to limit various impacts, appearance 
of VV.
VLU 1804 13 Pain, odour and exudate – impact on sleep, mobility and mood.
AAA, abdominal aortic aneurysm; CAD, carotid artery disease; PAD, peripheral arterial disease; VLU, venous leg ulcer; VV, varicose veins.
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Table 6 Structure of the main ePAQ- VAS with evidence base for inclusion of individual items, scales and sections
Section Scale
Clinicians’ 
consensus 
study
Most valid condition 
speciic PROMs Qualitative study Qualitative reviews Question text
VLU- 
QOL PADQOL AVVQ AAA CAD VV VLU PAD AAA CAD VV VLU PAD
Generic Pain 4 × × × × × × × × × × × × × Do you suffer with any pain?
Generic Pain 4 × − − × × × × × × × × × × Use the image below and click on 
body parts where you experience 
pain or discomfort.
Generic Pain − × − − × × × × × × × × × × Please use your own words to 
describe this problem.
Generic Pain 4 × × × × × × × × × × × × × How often do you experience a 
signiicant amount of pain?
Generic Pain 4 − − − × × × × × × × × × × How much do problems caused by 
pain affect your overall enjoyment 
of life?
Generic Sensation 4 − − − × × × × × × × Do you experience any numbness 
or pins and needles in any part of 
your body?
Generic Sensation 4 − − − × × × × × × × Please use the image below to 
select where you experience 
sensation change in your body.
Generic Sensation − − − − × × × × × × × Please use your own words to 
describe this problem.
Generic Sensation 4 − − − × × × × × × × How often do you experience 
numbness or pins and needles?
Generic Sensation 4 − − − × × × × × × × How much do problems caused 
by numbness or pins and needles 
affect your overall enjoyment of 
life?
Generic Weakness 4 − − − × × × Do you have any loss of strength or 
weakness in any part of your body?
Generic Weakness 3 − − − × × × Please use the image below to 
indicate the areas where you 
experience any physical weakness.
Generic Weakness − − − − × × × Please use your own words to 
describe this problem.
Generic Weakness 4 − − − × × × How often do you experience loss 
of strength or weakness?
Generic Weakness 3 − − − × × × How much do problems caused 
by weakness affect your overall 
enjoyment of life?
Continued
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Section Scale
Clinicians’ 
consensus 
study
Most valid condition 
speciic PROMs Qualitative study Qualitative reviews Question text
VLU- 
QOL PADQOL AVVQ AAA CAD VV VLU PAD AAA CAD VV VLU PAD
Carotid Anxiety 4 × × Do you worry about having a 
stroke?
Carotid Anxiety 3 × × Does carotid artery disease make 
you feel anxious?
Carotid Anxiety New item Are you worried about your health 
getting worse because of carotid 
artery disease?
Carotid Anxiety New item Are you worried about losing your 
independence because of carotid 
artery disease?
Carotid Symptoms 2 × Do you have any problems with 
maintaining your balance?
Carotid Symptoms 2 × Do you suffer with any problems 
with your memory? (eg, forgetting 
or losing things)
Carotid Symptoms 4 × × Have you had any problems with 
your speech? (eg, slurring your 
words or not being able to speak or 
say things properly)
Carotid Symptoms New item Do you have any problems with 
swallowing food?
Carotid Symptoms 4 × × Have you had any problems with 
partial or complete loss of vision in 
either of your eyes?
Carotid Symptoms 4 × × How would you describe any loss of 
vision in your right eye?
Carotid Symptoms 4 × × How would you describe any loss of 
vision in your left eye?
Carotid ADL 3 × × How much do problems caused 
by carotid artery disease (anxiety 
associated with diagnosis or 
physical symptoms) affect your 
overall enjoyment of life?
Table 6 Continued
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Section Scale
Clinicians’ 
consensus 
study
Most valid condition 
speciic PROMs Qualitative study Qualitative reviews Question text
VLU- 
QOL PADQOL AVVQ AAA CAD VV VLU PAD AAA CAD VV VLU PAD
Carotid ADL 4 × × How much do problems caused 
by carotid artery disease (eg, 
mini- stroke or stroke memory 
balance speech visual or other 
related issues) affect your physical 
activities such as exercise walking 
or running?
Carotid ADL 3 × × How much do problems caused 
by carotid artery disease (eg, 
mini- stroke or stroke memory 
balance speech visual or other 
related issues) affect your ability 
to undertake personal roles and 
responsibilities such as caring for 
others study or work?
Carotid ADL 4 × × How much do problems caused 
by carotid artery disease (eg, mini- 
stroke or stroke memory balance 
speech visual or other related 
issues) affect your ability to look 
after yourself?
Carotid ADL 3 × × How much do problems caused 
by carotid artery disease (eg, mini- 
stroke or stroke memory balance 
speech visual or other related 
issues) affect your social activities 
such as visiting friends and family?
Carotid ADL 2 × × How much do problems caused 
by carotid artery disease visual or 
other related issues) affect your 
mood?
AAA Symptoms 4 × × Do you have any abdominal 
(tummy) pain?
AAA Symptoms New item (3) Do you experience a throbbing 
feeling in your abdomen (tummy)?
AAA Anxiety 4 × × Do you worry about aortic 
aneurysm?
AAA Anxiety 4 × × Do you worry about any symptoms 
you experience that may be caused 
by aortic aneurysm?
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Section Scale
Clinicians’ 
consensus 
study
Most valid condition 
speciic PROMs Qualitative study Qualitative reviews Question text
VLU- 
QOL PADQOL AVVQ AAA CAD VV VLU PAD AAA CAD VV VLU PAD
AAA Anxiety 4 × × Do you worry about possible 
increase in the size of your 
aneurysm?
AAA Anxiety 4 × × Do you fear sudden death or 
rupture of your aortic aneurysm?
AAA Anxiety 4 × × Do you avoid physical exertion 
because of having an aortic 
aneurysm?
AAA Anxiety 3 × × Do you avoid travelling 
independently because of aortic 
aneurysm?
AAA ADL 3 × How much do problems caused by 
aortic aneurysm affect your overall 
enjoyment of life?
AAA ADL 4 × × How much does aortic aneurysm 
affect your physical activities? (eg, 
exercise walking or going out)
AAA ADL 3 × × How much does aortic aneurysm 
affect your ability to undertake 
personal roles and responsibilities? 
(eg, caring for others study or 
work?
AAA ADL 3 × How much do you feel aortic 
aneurysm affects your ability to 
look after yourself? (eg, rest wash 
toilet or feed yourself)
AAA ADL 4 × How much does aortic aneurysm 
affect your social activities? (eg, 
visiting friends or family)
AAA ADL 4 × × Do you suffer from low mood 
because of having an aortic 
aneurysm?
LL Ischaemic 
Pain
4 ± ± × × × × × Do you experience any cramping 
pain in your legs or feet?
LL Ischaemic 
Pain
4 ± × × × Do you experience cramping pain in 
your legs or feet when walking?
LL Ischaemic 
Pain
4 ± × × How far can you walk before you 
experience any cramping pain in 
your legs or feet?
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Section Scale
Clinicians’ 
consensus 
study
Most valid condition 
speciic PROMs Qualitative study Qualitative reviews Question text
VLU- 
QOL PADQOL AVVQ AAA CAD VV VLU PAD AAA CAD VV VLU PAD
LL Ischaemic 
Pain
4 ± × × Do you walk more slowly than you 
would choose to in order to avoid 
cramping pain in your legs and 
feet?
LL Ischaemic 
Pain
4 − × × Do you experience cramping pain 
in your legs or feet when walking 
uphill?
LL Ischaemic 
Pain
4 − × × Do you experience pain in your legs 
or feet when you climb stairs?
LL Ischaemic 
Pain
4 − × × × × × × Do you experience pain in your feet 
at night?
LL Ischaemic 
Pain
4 − Do you dangle one or both of your 
legs over the side of the bed to help 
reduce foot pain?
LL Ischaemic 
Pain
4 − × × × × × × Do you experience severe pain 
in your legs or feet when you are 
resting or sitting?
LL Ischaemic 
Pain
2 − × Are you troubled by cold feet?
LL Ulcer 4 X − × × × × × Have you ever had any ulcers on 
your legs or feet now or at any time 
in the past?
LL Ulcer 4 − × × × × × Please use the image below to 
show where you currently have any 
leg or foot ulcers.
LL Ulcer 4 − − × × × Are you concerned about the smell 
of your leg ulcers?
LL Ulcer 4 × − × × Are you concerned about the 
appearance of your leg ulcers?
LL Ulcer 4 − − × × Do you have leg ulcers that leak 
luid (watery liquid)?
LL Ulcer 4 − − × × Do you experience infections in 
your leg ulcers? (eg, foul smell or 
pus)
LL Ulcer 4 − − × × × Do you experience repeated leg 
ulcers?
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VLU- 
QOL PADQOL AVVQ AAA CAD VV VLU PAD AAA CAD VV VLU PAD
LL Ulcer 4 × − × × × Do you worry about your leg ulcers? 
(eg, not healing becoming infected 
losing part of your leg or foot).
LL VV 4 − − × Do you experience any bleeding 
from veins in your legs or feet?
LL VV 4 − × × × Do you have any problems with the 
skin over your varicose veins?
LL VV 4 − × × × Do varicose veins make you feel 
self- conscious or embarrassed?
LL VV 4 × − × × × × × Do leg or foot problems affect what 
clothing or shoes you can wear?
LL VV 4 − × × × × Do you experience any swelling in 
your legs or feet?
LL VV 4 − × × × × × Do you experience itching in your 
legs or feet?
LL VV 4 − × × × × Do you wear compression 
stockings or tights for your legs?
LL Tissue loss 4 − − × × × Have you lost any part of your 
legs or feet through amputation or 
gangrene?
LL Tissue loss 4 – × × × Please click on the appropriate part 
or parts of your legs feet or toes 
that you have had amputated or 
have been lost.
LL Anxiety 3 × × × × × × × × × Do you worry about your leg 
problems getting worse in the 
future?
LL ADL 3 ± × ± × × × × × × How much do leg or foot problems 
affect your overall enjoyment of 
life?
LL ADL 3 ± × − × × × × × × How much do leg or foot problems 
affect your ability to carry out 
physical activities? (eg, walking 
housework or exercise)
LL ADL 3 ± × ± × × × × × × How much do leg or foot 
problems affect your personal 
responsibilities? For example, 
caring for others study or work.
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Section Scale
Clinicians’ 
consensus 
study
Most valid condition 
speciic PROMs Qualitative study Qualitative reviews Question text
VLU- 
QOL PADQOL AVVQ AAA CAD VV VLU PAD AAA CAD VV VLU PAD
LL ADL 3 − × ± × × × × × × How much do leg or foot problems 
affect your ability to look after 
yourself? (eg, rest wash toilet or 
feed yourself)
LL ADL 3 ± × ± × × × × × × How much do leg or foot problems 
affect your social activities? (eg, 
going out visiting friends or family)
LL ADL 4 X× × − × × × × × × Do you suffer from low mood 
because of leg or foot problems?
Generic Personal 
data
− × − × × × × × × × × Do you rely on any people to help 
you with your everyday activities?
Generic Personal 
data
− × × × × × × × Do you experience inancial 
problems because of your vascular 
condition?
The items of the eight scales are coloured in this table.
AAA, abdominal aortic aneurysm; ADL, activity of daily living; AVVQ, Aberdeen Varicose Veins Questionnaire; CAD, carotid artery disease; LL, lower limb; PAD, peripheral arterial disease; PADQOL, 
peripheral arterial disease quality of life; VLU, venous leg ulcer; VLU- QOL, venous leg ulcer quality of life; VV, varicose veins.
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Face validity of ePAQ-VAS
A second phase of semistructured patient interviews was 
conducted by (EL and PP) with 19 participants, purpose-
fully sampled from the vascular populations previously 
described. This sample included patients with AAA, CAD, 
PAD, VLU and VVs. ePAQ- VAS (version 1) was presented 
to these patients, and a focused interview was conducted 
to investigate vascular patients’ perceptions of the ques-
tionnaire in its entirety as well as the relevant items to 
the individual being interviewed. Questions were asked 
under the following headings of:
 Ź Overall impressions.
 Ź Clarity.
 Ź Relevance and emotional response.
Interviews were audio taped, transcribed and analysed. 
A pragmatic approach was used for the analysis, with 
comments collated and presented back to the working 
group who made consensus decisions on revisions to 
ePAQ- VAS. Written consent was obtained from the 
participants.
Patient and public involvement
The research question and output were developed in 
consultation with patients and public. The authors would 
like to thank the Cardiovascular Research Patient Panel 
at Sheffield Teaching Hospitals NHS Foundation Trust. 
The aim of the research was to develop a patient focused 
outcome measure. In this process, patients were recruited 
for two qualitative studies to ensure content validity and 
face validity of this tool. Patients were involved in every 
stage of the development of the study. The developed 
ePAQ- VAS has been used by patients in a clinical study, 
and there are plans for regular clinical use. The results 
will also be disseminated in relevant meetings and among 
patient groups.
RESULTS
In total, 12 clinicians completed the first survey and iden-
tified PAD, AAA, VLU, VV and CAD as the most common 
vascular conditions treated by them. They listed common 
issues such as pain on walking, rest pain, reduced mobility 
or lack of mobility for patients with PAD and no physical 
symptoms for those with AAA but need for multidisci-
plinary approach to manage these patients. For patients 
with VLU, the main issues included burning pain, recur-
rence and healing; for patients suffering with VV, skin 
changes, appearance of leg and ulcer as well as ache were 
the main issues raised. The clinicians felt the key issue 
for patients with CAD was identifying patients benefiting 
from intervention and reducing the risk of stroke. The 
result from this survey was used to inform the analysis of 
qualitative data used to develop ePAQ- VAS.
Systematic reviews and assessment of psychometric eval-
uation were conducted for PROMs validated for use in 
PAD, AAA, VLU, VV and CAD. A total of 33 PROMs that 
had undergone some form of validation were identified 
in 41 studies (table 1).
No PROMs were identified that had undergone suffi-
ciently rigorous development and validation to suggest 
that they were suitable for direct use in ePAQ- VAS, the 
details of these reviews have been reported previously4–8. 
Where evidence existed, this fell short of required 
standards.3 14 For instance, the review investigating VV 
PROMs4 found some evidence for, and discussion of, 
content validity in relation to the Aberdeen Varicose 
Vein Questionnaire (AVVQ) and suggest that it is the 
most appropriate existing condition- specific measure for 
use in a VV population. However, item generation for 
these PROMs involved a literature review and assessment 
Figure 2 Evidence synthesis to develop of ePAQ- VAS. 
ePAQ- VAS, electronic personal assessment questionnaire 
for vascular patients; PROMs, patient- reported outcome 
measures.
Figure 3 Overview of ePAQ- VAS structure. AAA, abdominal 
aortic aneurysm; CAD, carotid artery disease; ePAQ- VAS, 
electronic personal assessment questionnaire for vascular 
patients; PAD, peripheral arterial disease; VLU, venous leg 
ulcers; VV, varicose veins.
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by clinicians of relevance of included items with no 
direct involvement of patients, therefore suggesting a 
deficiency in terms of content validity.17 The scales from 
these reviews were used to provide a framework for the 
systematic qualitative reviews and the primary qualitative 
study.5 9–13
In total, 111 patients were approached, but only 55 
patients (69.1% male) were interviewed about their expe-
rience of living with vascular disease, ages ranged from 
35 to 77 years. For further information about the study 
participants, please see table 2.
Six overarching themes relating to the impact of the 
five vascular conditions were identified. These were 
symptoms (including pain), impact on physical function, 
social impact, psychological impact, financial impact 
and lifestyle. Pain and mobility were the most commonly 
reported themes by participants with PAD. The extent 
to which they impacted daily living was dependent on 
the severity of the disease, age expectations and social 
support. Fear of symptoms worsening and future amputa-
tion had a significant impact on daily living.
Most participants with AAA reported having no phys-
ical symptoms; a small number of participants reported 
abdominal pain and pain in their legs. Uncertainty, 
anxiety and fear of sudden death had the most impact on 
their quality of life. This was similar for patients with CAD 
who reported few lasting symptoms since the majority 
had what they described as a ‘mini- stroke’. However, CAD 
patients reported the widest range of signs and symp-
toms, with nine different symptoms. This condition had 
the least impact on physical and social function, although 
psychologically it caused a sense of worry and anxiety. 
This was mainly caused by fear of having a major stroke.
Pain was the most common issue reported by patients 
with VVs; other issues included swelling of the legs and 
the impact of this on mobility. The perceived unpleasant 
appearance of the VV seemed to have had the greatest 
psychological impact and was described by many of the 
participants. The impact of VLU on daily living and 
quality of life differed within the group that was inter-
viewed. For some, there were no major issues, and having 
a VLU was accepted as part of their life, with the hope 
that it would heal eventually. For others, there was a far 
more significant effect with reports of severe sharp pain 
that significantly reduced their quality of life. This had a 
bearing on people’s mobility and their ability, or desire, 
to go out and socialise. Sleep was also disturbed due to 
pain. The progression of VLU had resulted in partici-
pants suffering for long periods of time. In addition, the 
non- healing or reoccurring nature of the condition had 
a significant impact for many. VLU appeared to have a 
significant psychological impact causing a high degree of 
distress for some patients. Summary results are shown in 
table 3.
Identified signs, symptoms and impact of the condi-
tions were then mapped and tabulated to see which 
themes were relevant to which condition and where the 
similarities and differences lay (table 4).
A total of 31 studies were included across the five reviews 
of existing qualitative research.6 10–13 A short summary of 
the main themes to emerge for each condition is shown 
in table 5.
The themes from the first round of the clinicians’ 
consensus study, as well as scales of identified PROMs, 
were used to inform the framework analysis of the qualita-
tive data. Items from existing PROMs were then mapped 
against emerging themes from the qualitative study, and 
the qualitative review synthesis for each condition, to 
explore which PROMs items or scales captured themes 
deemed to be the most pertinent to patients. A triangu-
lation approach was followed, whereby researchers eval-
uated whether the concepts were the same (agreement), 
offered similar concepts (partial agreement), were in 
contradiction (dissonance) or were not present (silence). 
An example of this triangulation approach is provided 
in the online supplementary material. The results of the 
triangulation study were only used to group symptoms 
together and avoid repetition. No items were deleted 
based on the triangulation.
The ePAQ- VAS development team used the findings 
from the triangulation for AAA, PAD, VV, VLU and CAD 
to develop themes for distinct sections relevant for each 
of these vascular conditions. The primary qualitative data 
were used to create each item. Items were then grouped 
into sections, and within each section, there were scales 
consisting of items that measured the same latent vari-
able such as anxiety related to the diagnosis of AAA. The 
results of the clinicians’ consensus study were considered 
to add further items to the relevant sections (table 6).
The items of ePAQ- VAS were arranged into four 
sections: generic, AAA, CAD and lower limb (LL) 
vascular conditions. A single LL section was developed as 
common themes were identified for conditions affecting 
the legs, regardless of whether the underlying pathology 
was venous or arterial. An inclusive approach to develop-
ment was used and a comprehensive questionnaire was 
produced with 168 questions (see figure 2 for an overview 
of the process to develop ePAQ- VAS).
ePAQ- VAS was presented to 19 vascular patients. 
Overall, the response was positive; the participants felt the 
generic, and the relevant disease specific were compre-
hensive, fit for purpose and potentially useful. There was 
little consistency in items that participants found difficult 
and no individual item was identified with which most 
participants had difficulty.
Discussion included the use of abbreviations, font size 
and contrast between text and background, response 
options and scales, electronic format versus paper format, 
relevance to patients and clinicians, the use of free- text 
boxes and the language and wording used, when and how 
to use the skip button, repetition of items and subject 
matter and the possibility of emotional distress associated 
with questions about the possibility of deterioration or 
death.
Based on the findings from the face validity exercise, 
and input from the vascular PROMs group, further 
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revisions were made in an iterative process, culminating 
in the development of ePAQ- VAS. The structure of the 
questionnaire is illustrated in figure 3. Fifty- nine items 
were eliminated for overlap; these include questions 
asking about common symptoms experienced across 
most vascular conditions. Five items were added based on 
suggestion from clinicians. Generic items for all respon-
dents were presented in the first section and include 
questions about pain, altered sensation, weakness, 
weight/height, smoking habit, previous medical history 
and regular medication. This information was deemed 
important for assessment of vascular conditions both by 
patients and clinicians.
The next three sections are condition specific relating 
to CAD, AAA and LL vascular disease sections. These 
sections are further divided into scales. There are 55 
items within eight scales and the remainder of questions 
do not contribute to scales but are kept due to their clin-
ical relevance. The eight scales are part of the condition- 
specific sections and include CAD- related anxiety, impact 
of CAD on activities of daily living (ADLs), AAA- related 
anxiety, impact of AAA on activities of ADL, PAD symp-
toms, VLU symptoms, VV symptoms and impact of LL 
vascular disease on ADL. Individual items, scales and 
sections of ePAQ- VAS in its initial version can be viewed 
on https:// demo- questionnaire. epaq. co. uk/ home/ 
project? id= VASC_ 1. 6& page= 1.
The evidence used to develop each item in ePAQ- VAS 
is made explicit in table 5; this table show whether the 
source for the item is the qualitative study, reviews or 
consensus study.
DISCUSSION
This study documents stages undertaken to develop 
ePAQ- VAS and the conceptual framework underpinning 
this new tool for use in undifferentiated vascular popu-
lations. The main strength of this new instrument is that 
it can be used as a holistic clinical assessment tool that 
can be completed by patients before meeting the vascular 
surgeon in the clinic. The information generated can 
be used to help shared decision making by focusing on 
patient priorities. This tool has the further advantage of 
being an electronic online PROM since it can be used to 
monitor impact of the disease and/or interventions over-
time. Furthermore, this instrument is preference based, 
unlike the identified vascular PROMs4–8; once further vali-
dated, the disease- specific scales can be used to generate 
utility values either by mapping to the values of a generic 
utility measure or by further utility studies.18
This instrument has been developed in line with FDA 
guidelines for developing PROMs.3 Items were devel-
oped based on themes extracted from primary qualita-
tive data, systematic qualitative evidence synthesis and 
clinicians’ consensus exercise.9–13 We have made efforts 
through purposive sampling to ensure that we have 
included diverse demographic groupings in the primary 
research, and this is augmented by the inclusion of 
systematic reviews that include evidence gathered in 
national and international studies. Another strength of 
this study is that the qualitative evidence in the review 
and the primary study included patients at different 
stages of their disease. The data collected included the 
impact of disease, including symptoms, on daily living 
and the impact of diagnosis and treatment on the daily 
living. The vascular clinicians’ input into developing and 
rating the items was sought, and new items were incor-
porated based on recommendation from 25 vascular 
clinicians.
The work of developing individual items and their 
assignment to putative scales and sections was based both 
on the framework of existing PROMs4–8 and on input 
from vascular clinicians. In this stage of the ePAQ- VAS 
development, an inclusive approach was chosen, and all 
relevant items were incorporated except for those with 
clear repetition. The main limitation of this draft version 
of ePAQ- VAS is that it is long and potentially repetitive; it 
is expected that factor analysis and psychometric testing 
will lead to a reduction in the number of individual items 
and will confirm (or refute) the putative scales identi-
fied in the current version. Furthermore, skipping rules 
embedded within the questionnaire will only present 
the items relevant to the patient completing the online 
instrument.
Another limitation is that ePAQ- VAS only cover the five 
main vascular conditions, and it might not be relevant to 
patients with other vascular disease. However, including 
all vascular conditions in one instrument is not possible, 
and the evidence to include only these conditions was 
based on input from clinicians treating vascular disease. 
As stated by the FDA,3 a fundamental consideration in the 
development of PROMs is the adequacy of item genera-
tion. Due to the heterogeneous nature of vascular disease, 
it was not straightforward to identify what exactly should 
be measured when developing and defining the initial 
conceptual framework for the ePAQ- VAS. To this end, as 
recommended by the FDA, the initial conceptual frame-
work was based on information gathered from reviews of 
the literature, patients and expert opinion.
The findings of the qualitative study indicated an 
overlap in patient experiences of the various conditions. 
However, there was also a clear difference in how each 
condition impacted on different aspects of quality of life. 
There were conditions with many physical symptoms and 
others with none. This demonstrated that while it may 
be possible to develop a PROM for use across a variety 
of vascular conditions, it would also need to include 
condition- specific items to fully capture the impact and 
clinically relevant information for each disease or condi-
tion. A further limitation is that the face validity study was 
not able to examine the comprehensiveness of ePAQ- VAS 
since it covered multiple conditions, and it was difficult 
to expect from any of the patient groups interviewed to 
comment on diseases they have not experienced. There-
fore, they only commented on the generic questions and 
the disease- specific items relating to their condition.
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In conclusion, ePAQ- VAS is a multidimensional measure 
developed for use in a range of vascular conditions. It is 
a single electronic tool, covering most vascular condi-
tions. This is important for those patients presenting with 
mixed symptoms or multiple conditions. The items in 
ePAQ- VAS can capture information about disease symp-
toms, HRQoL, comorbidities, medical history and other 
relevant healthcare issues. This type of information can 
aid communication between healthcare professionals 
and patients and support shared decision making. The 
electronic format may make it easier to monitor patients 
over time, especially those with chronic conditions and 
those treated with lifestyle modification or conservatively. 
Based on methods used in its construction, this tool has a 
strong degree of content validity; however, further psycho-
metric testing for reliability, responsiveness and validity is 
needed. Once this electronic PROMs is validated, it can 
be used as an outcome measure in clinical practice and 
research.
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